Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Heart valve fix: why some patients still have trouble?

NCT ID NCT05326126

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study examined how tiny blood vessels in the heart work after a TAVI procedure, which replaces a narrowed heart valve without open surgery. Researchers measured blood flow and scarring in the heart muscle of 75 patients. The goal was to see if poor small-vessel function is linked to heart muscle damage, which could explain why some people still feel symptoms after valve replacement.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better understand why some patients still have heart problems after TAVI, pointing toward new ways to treat or prevent those issues.
What could go wrong
This was a small, observational study that only measured outcomes without testing a new treatment. The findings may not apply to all TAVI patients and need further research to confirm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

75 people

The number who actually took part.

Started

Jul 2021

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: • All patients referred to IRCCS Ospedale San Raffaele who are candidates to receive a TAVI implant for severe, symptomatic aortic stenosis under current appropriateness criteria and clinical practice guidelines will be considered eligible to take part in the study Exclusion Criteria: * Age \<18 years * Inability to express informed consent to take part in the present study. * Pregnancy or lactation * Pre-existing known disease determining a prognosis quo ad vitam shorter than the follow up of the present study * Significant chronic kidney disease (estimated glomerular filtration rate \<30 ml/min) * Known significant epicardial coronary artery stenosis * Known contraindication to adenosine administration: * Known allergic reactions * Second or third degree atrioventricular block before the procedure (in absence of a functional permanent pacemaker) * Long QT syndrome * Unstable angina * Severe hypotension * Acutely decompensated heart failure * Chronic obstructive pulmonary disease with bronchospasm * Concomitant use of dypiridamole

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Severe symptomatic aortic stenosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • IRCCS San Raffaele

    Milan, 20132, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.